Free Trial
→ F1 Engineering Powers This Electric Marine Motor (From The Tomorrow Investor) (Ad) Buy COGT Stock  Free COGT Stock Alerts

Cogent Biosciences (COGT) Financials

Cogent Biosciences logo
$4.88 +0.00 (+0.08%)
As of 10:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Cogent Biosciences

Annual Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -256 -192 -140
Consolidated Net Income / (Loss)		 -256 -192 -140
Net Income / (Loss) Continuing Operations		 -256 -194 -142
Total Pre-Tax Income 		-256 -194 -142
Total Operating Income		 -276 -208 -148
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 276 208 148
Selling, General & Admin Expense		 43 34 26
Research & Development Expense		 233 174 122
Total Other Income / (Expense), net		 20 16 7.60
Interest & Investment Income		 18 13 3.99
Other Income / (Expense), net		 1.99 0.94 2.25
Basic Earnings per Share		 ($2,426.26) ($488.17) ($433.56)
Weighted Average Basic Shares Outstanding		 103.94M 79.74M 58.83M
Diluted Earnings per Share		 ($2,426.26) ($488.17) ($433.56)
Weighted Average Diluted Shares Outstanding		 103.94M 79.74M 58.83M
Weighted Average Basic & Diluted Shares Outstanding		 113.85M 103.91M 69.95M

Quarterly Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -68 -71 -59 -58 -54 -55 -44 -39 -40 -35
Consolidated Net Income / (Loss)		 -68 -71 -59 -58 -54 -55 -44 -39 -40 -35
Net Income / (Loss) Continuing Operations		 -68 -71 -59 -58 -56 -55 -44 -39 -41 -35
Total Pre-Tax Income 		-68 -71 -59 -58 -56 -55 -44 -39 -41 -35
Total Operating Income		 -74 -75 -64 -62 -58 -60 -47 -43 -44 -37
Total Operating Expenses		 74 75 64 62 58 60 47 43 44 37
Selling, General & Admin Expense		 12 12 10 9.70 9.51 9.45 8.21 7.20 7.00 6.89
Research & Development Expense		 62 64 54 53 49 50 39 36 37 30
Total Other Income / (Expense), net		 5.81 4.78 5.44 4.06 3.86 4.20 3.01 4.65 4.13 1.76
Interest & Investment Income		 3.86 4.78 5.39 4.06 3.87 4.20 2.74 2.27 2.11 1.50
Other Income / (Expense), net		 1.95 0.00 0.04 -0.00 -1.71 0.00 0.27 2.38 0.66 0.26
Basic Earnings per Share		 ($2,424.41) ($0.64) ($0.59) ($0.62) ($486.39) ($0.64) ($0.59) ($0.55) ($0.67) ($0.50)
Weighted Average Basic Shares Outstanding		 103.94M 110.17M 99.24M 94.80M 79.74M 86.17M 74.75M 70.73M 58.83M 69.58M
Diluted Earnings per Share		 ($2,424.41) ($0.64) ($0.59) ($0.62) ($486.39) ($0.64) ($0.59) ($0.55) ($0.67) ($0.50)
Weighted Average Diluted Shares Outstanding		 103.94M 110.17M 99.24M 94.80M 79.74M 86.17M 74.75M 70.73M 58.83M 69.58M
Weighted Average Basic & Diluted Shares Outstanding		 113.85M 110.46M 109.45M 95.61M 103.91M 86.12M 85.47M 70.95M 69.95M 69.89M

Annual Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 45 -88 -80
Net Cash From Operating Activities		 -208 -154 -119
Net Cash From Continuing Operating Activities		 -208 -153 -119
Net Income / (Loss) Continuing Operations		 -256 -192 -140
Consolidated Net Income / (Loss)		 -256 -192 -140
Depreciation Expense		 2.45 2.27 0.84
Amortization Expense		 -5.72 -5.17 3.40
Non-Cash Adjustments To Reconcile Net Income		 40 30 18
Changes in Operating Assets and Liabilities, net		 12 12 -0.61
Net Cash From Investing Activities		 38 -98 -125
Net Cash From Continuing Investing Activities		 38 -98 -125
Purchase of Property, Plant & Equipment		 -0.57 -2.80 -6.86
Purchase of Investments		 -256 -349 -178
Sale and/or Maturity of Investments		 294 254 60
Net Cash From Financing Activities		 214 164 164
Net Cash From Continuing Financing Activities		 214 164 164
Issuance of Common Equity		 214 163 162
Other Financing Activities, net		 0.20 0.97 1.26

Quarterly Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 1.12 8.83 -128 163 -34 -128 52 21 -0.68 -185
Net Cash From Operating Activities		 -61 -52 -43 -53 -44 -38 -32 -40 -29 -34
Net Cash From Continuing Operating Activities		 -61 -52 -43 -53 -44 -38 -32 -40 -29 -34
Net Income / (Loss) Continuing Operations		 -68 -71 -59 -58 -54 -55 -44 -39 -40 -35
Consolidated Net Income / (Loss)		 -68 -71 -59 -58 -54 -55 -44 -39 -40 -35
Depreciation Expense		 0.63 0.62 0.61 0.60 0.60 0.58 0.56 0.53 0.42 0.26
Amortization Expense		 -2.12 -5.72 3.06 -0.93 -5.42 1.18 -0.08 -0.85 -0.67 3.00
Non-Cash Adjustments To Reconcile Net Income		 9.98 10 10 9.39 8.06 8.76 7.16 5.85 5.04 4.23
Changes in Operating Assets and Liabilities, net		 -1.13 13 2.58 -3.24 7.44 6.89 4.37 -6.46 5.42 -6.86
Net Cash From Investing Activities		 62 60 -85 1.04 10 -91 -78 60 28 -152
Net Cash From Continuing Investing Activities		 62 60 -85 1.04 10 -91 -78 60 28 -152
Purchase of Property, Plant & Equipment		 -0.08 -0.28 -0.15 -0.07 -0.32 -0.12 -1.26 -1.10 -1.97 -3.31
Purchase of Investments		 -13 -19 -150 -73 -51 -112 -126 -59 -30 -148
Sale and/or Maturity of Investments		 74 80 66 74 62 22 50 120 60 -
Net Cash From Financing Activities		 0.03 0.62 -0.26 214 - 1.00 162 0.45 0.32 0.99
Net Cash From Continuing Financing Activities		 0.03 0.62 -0.26 214 - 1.00 162 0.45 0.32 0.99
Issuance of Common Equity		 -0.00 0.56 -0.37 214 - 0.27 162 0.31 - 0.05
Other Financing Activities, net		 0.03 0.06 0.11 0.00 - 0.73 0.10 0.13 0.32 0.94

Annual Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 328 313 301
Total Current Assets		 296 271 265
Cash & Equivalents		 98 53 140
Restricted Cash		 0.00 0.00 1.26
Short-Term Investments		 189 212 119
Prepaid Expenses		 9.40 5.06 4.44
Plant, Property, & Equipment, net		 6.47 8.34 7.78
Total Noncurrent Assets		 25 34 28
Long-Term Investments		 0.00 7.46 0.00
Other Noncurrent Operating Assets		 25 27 28
Total Liabilities & Shareholders' Equity		 328 313 301
Total Liabilities		 72 56 45
Total Current Liabilities		 56 38 27
Accounts Payable		 12 11 5.84
Accrued Expenses		 42 26 18
Other Current Liabilities		 1.57 1.39 3.12
Total Noncurrent Liabilities		 16 17 18
Other Noncurrent Operating Liabilities		 16 17 18
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 256 258 256
Total Preferred & Common Equity		 256 258 256
Preferred Stock		 111 60 66
Total Common Equity		 146 198 190
Common Stock		 1,005 801 601
Retained Earnings		 -859 -604 -411
Accumulated Other Comprehensive Income / (Loss)		 0.45 0.25 -0.10

Quarterly Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 384 430 476 355 392 263 332
Total Current Assets		 342 370 442 286 335 226 296
Cash & Equivalents		 97 88 216 87 214 161 141
Short-Term Investments		 238 275 220 192 115 60 149
Prepaid Expenses		 6.01 6.76 6.16 6.91 5.12 4.75 6.07
Plant, Property, & Equipment, net		 7.02 7.36 7.82 8.64 9.10 9.03 6.54
Total Noncurrent Assets		 35 53 26 61 49 28 29
Long-Term Investments		 10 27 0.00 34 22 - -
Other Noncurrent Operating Assets		 25 26 26 27 27 28 29
Total Liabilities & Shareholders' Equity		 384 430 476 355 392 263 332
Total Liabilities		 69 57 54 53 44 40 42
Total Current Liabilities		 53 40 37 35 26 21 24
Accounts Payable		 15 8.98 16 9.87 7.16 4.17 4.09
Accrued Expenses		 36 30 20 24 17 16 14
Other Current Liabilities		 1.52 1.48 1.43 1.34 1.18 0.95 5.07
Total Noncurrent Liabilities		 16 17 17 18 18 19 18
Other Noncurrent Operating Liabilities		 16 17 17 18 18 19 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 315 373 422 303 348 224 290
Total Preferred & Common Equity		 315 373 422 303 348 224 290
Preferred Stock		 111 114 222 60 62 62 66
Total Common Equity		 204 259 200 243 286 161 224
Common Stock		 995 980 862 792 780 611 596
Retained Earnings		 -792 -721 -662 -549 -494 -450 -372
Accumulated Other Comprehensive Income / (Loss)		 0.90 -0.19 -0.04 -0.17 -0.10 0.02 -0.16

Annual Metrics And Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -31.95% -48.63% -98.83%
EBIT Growth		 -32.22% -42.31% -99.21%
NOPAT Growth		 -32.58% -40.78% -95.68%
Net Income Growth		 -32.98% -37.20% -94.04%
EPS Growth		 -397.01% -12.60% -23,085.03%
Operating Cash Flow Growth		 -35.26% -29.49% -101.89%
Free Cash Flow Firm Growth		 -31.54% -29.68% -89.75%
Invested Capital Growth		 -100.36% -220.43% 12.80%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -3.17% -11.36% -15.07%
EBIT Q/Q Growth		 -4.52% -8.85% -13.86%
NOPAT Q/Q Growth		 -5.95% -7.48% -13.96%
Net Income Q/Q Growth		 -5.60% -8.30% -11.71%
EPS Q/Q Growth		 -97,340.16% -23,597.57% -23,986.67%
Operating Cash Flow Q/Q Growth		 -8.63% -10.55% -7.85%
Free Cash Flow Firm Q/Q Growth		 -10.15% -7.22% -8.47%
Invested Capital Q/Q Growth		 0.32% -54.65% -1,078.38%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.12% 99.04%
Interest Burden Percent		 93.40% 93.69% 97.26%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -99.54% -74.94% -59.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -66.50% -56.57% -40.48%
Return on Equity Simple (ROE_SIMPLE)		 -99.83% -74.63% -54.84%
Net Operating Profit after Tax (NOPAT)		 -193 -146 -103
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -22.38% -17.51% -15.31%
Return On Investment Capital (ROIC_SIMPLE)		 -75.37% -56.51% -40.47%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -274 -207 -146
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -277 -210 -141
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 5.91 2.56 4.25
Price to Tangible Book Value (P/TBV)		 5.91 2.56 4.25
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.04 -1.02
Leverage Ratio		 1.25 1.20 1.13
Compound Leverage Factor		 1.17 1.12 1.10
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 43.15% 23.29% 25.74%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 56.85% 76.71% 74.26%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 1.67 1.47 8.19
Noncontrolling Interest Sharing Ratio		 33.19% 24.51% 32.18%
Liquidity Ratios		 - - -
Current Ratio		 5.32 7.09 9.87
Quick Ratio		 5.15 6.96 9.66
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -178 -135 -104
Operating Cash Flow to CapEx		 -36,263.70% -5,494.42% -1,728.66%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -31 -15 -4.80
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -15 -11 0.70
Enterprise Value (EV)		 685 293 613
Market Capitalization		 862 506 808
Book Value per Share		 $1.32 $2.30 $2.72
Tangible Book Value per Share		 $1.32 $2.30 $2.72
Total Capital		 256 258 256
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -287 -273 -261
Capital Expenditures (CapEx)		 0.57 2.80 6.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -46 -33 -22
Debt-free Net Working Capital (DFNWC)		 241 233 238
Net Working Capital (NWC)		 241 233 238
Net Nonoperating Expense (NNE)		 63 47 37
Net Nonoperating Obligations (NNO)		 -287 -273 -261
Total Depreciation and Amortization (D&A)		 -3.27 -2.90 4.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2,426.26) ($2.42) ($2.39)
Adjusted Weighted Average Basic Shares Outstanding		 103.94M 79.66M 58.74M
Adjusted Diluted Earnings per Share		 ($2,426.26) ($2.42) ($2.39)
Adjusted Weighted Average Diluted Shares Outstanding		 103.94M 79.66M 58.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 113.85M 103.91M 69.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -193 -146 -103
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -13.16% -39.26% -30.96% -52.36% -49.45% -73.59% -34.20% -36.43% -74.62% -78.26%
EBIT Growth		 -19.77% -26.57% -37.44% -52.75% -39.10% -62.96% -33.01% -32.90% -69.89% -90.44%
NOPAT Growth		 -26.63% -26.58% -36.75% -44.33% -33.11% -61.81% -31.32% -37.62% -70.61% -85.79%
Net Income Growth		 -24.95% -27.54% -33.75% -51.21% -37.22% -57.95% -26.19% -25.96% -59.03% -83.72%
EPS Growth		 -398.45% 0.00% 0.00% -12.73% -72,495.52% -28.00% 16.90% 19.12% -4.69% -4.17%
Operating Cash Flow Growth		 -37.46% -36.90% -33.17% -32.93% -49.86% -10.25% -21.21% -39.47% -41.54% -144.10%
Free Cash Flow Firm Growth		 -19.89% 1.05% 18.56% 20.46% 3.63% -3.73% -65.05% -55.78% -56.85% -43.70%
Invested Capital Growth		 -100.36% -210.85% -571.81% -755.87% -220.43% -2,341.52% 66.59% 164.20% 12.80% 92.80%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 8.98% -32.69% 3.27% 3.13% -12.01% -24.77% -12.54% 4.98% -30.10% 3.54%
EBIT Q/Q Growth		 4.81% -17.20% -3.11% -4.12% -0.60% -27.26% -14.59% 5.18% -17.85% -3.87%
NOPAT Q/Q Growth		 2.23% -17.13% -3.18% -7.17% 2.27% -26.54% -8.90% 1.16% -18.80% -2.69%
Net Income Q/Q Growth		 3.83% -19.82% -1.03% -7.33% 1.84% -25.65% -14.23% 2.60% -12.99% -0.39%
EPS Q/Q Growth		 -378,714.06% -8.47% 4.84% 3.13% -75,898.44% -8.47% -7.27% 17.91% -34.00% 29.58%
Operating Cash Flow Q/Q Growth		 -16.53% -21.74% 18.71% -19.19% -16.06% -18.42% 18.86% -34.38% 14.61% -30.18%
Free Cash Flow Firm Q/Q Growth		 -13.67% -3.13% -9.35% 6.48% 6.18% 15.12% -6.80% -13.31% -0.99% -35.05%
Invested Capital Q/Q Growth		 0.32% -85.17% -24.43% 12.77% -54.65% -300.20% -221.48% 142.62% -1,078.38% 94.52%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 96.97% 100.00% 100.00% 100.00% 96.68% 100.00%
Interest Burden Percent		 94.62% 93.66% 91.62% 93.50% 93.54% 92.95% 94.15% 94.45% 95.10% 95.90%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -99.54% -78.47% -62.92% -65.70% -74.94% -59.94% -47.12% -72.04% -59.69% -51.54%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,723.51% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -66.50% -56.79% -47.54% -36.76% -56.57% -47.21% -37.69% -47.40% -40.48% -44.57%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -77.00% -60.83% -50.24% 0.00% -58.65% -45.16% -66.29% 0.00% -43.30%
Net Operating Profit after Tax (NOPAT)		 -52 -53 -45 -44 -41 -42 -33 -30 -31 -26
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.82% -5.42% -3.75% -4.46% -5.10% -4.53% -3.28% -4.03% -3.75% -3.77%
Return On Investment Capital (ROIC_SIMPLE)		 -20.14% - - - -15.81% - - - -11.97% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -72 -75 -64 -62 -60 -60 -47 -41 -43 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -73 -81 -61 -63 -65 -58 -46 -41 -43 -33
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 5.91 5.79 3.11 2.89 2.56 3.43 2.94 4.68 4.25 4.38
Price to Tangible Book Value (P/TBV)		 5.91 5.79 3.11 2.89 2.56 3.43 2.94 4.68 4.25 4.38
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 291.35 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.07 -1.03 -1.02 -1.04 -1.02 -1.01 -1.00 -1.02 -1.01
Leverage Ratio		 1.25 1.20 1.14 1.14 1.20 1.16 1.14 1.14 1.13 1.12
Compound Leverage Factor		 1.18 1.12 1.04 1.07 1.12 1.08 1.07 1.08 1.08 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 43.15% 35.15% 30.58% 52.60% 23.29% 19.82% 17.88% 27.87% 25.74% 22.70%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 56.85% 64.85% 69.42% 47.40% 76.71% 80.18% 82.12% 72.13% 74.26% 77.30%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.71 7.59 6.61 5.10 3.02 7.65 10.26 9.46 9.32 13.20
Noncontrolling Interest Sharing Ratio		 33.19% 27.63% 24.45% 44.04% 24.51% 21.23% 20.02% 34.20% 32.18% 13.51%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 5.32 6.44 9.25 12.05 7.09 8.24 12.99 10.71 9.87 12.59
Quick Ratio		 5.15 6.32 9.08 11.88 6.96 8.04 12.79 10.43 9.66 12.28
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -32 -31 -28 -30 -32 -38 -35 -31 -31
Operating Cash Flow to CapEx		 -80,769.33% -18,565.71% -28,852.03% -75,041.43% -13,990.48% -31,380.99% -2,550.99% -3,582.68% -1,495.07% -1,040.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -31 -31 -17 -13 -15 -9.94 -2.48 2.04 -4.80 -0.41
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -15 -21 -14 -15 -11 -9.53 4.95 5.23 0.70 5.24
Enterprise Value (EV)		 685 947 530 365 293 580 551 596 613 757
Market Capitalization		 862 1,182 806 579 506 833 840 755 808 981
Book Value per Share		 $1.32 $1.86 $2.71 $2.11 $2.30 $2.84 $4.03 $2.31 $2.72 $3.41
Tangible Book Value per Share		 $1.32 $1.86 $2.71 $2.11 $2.30 $2.84 $4.03 $2.31 $2.72 $3.41
Total Capital		 256 315 373 422 258 303 348 224 256 290
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -287 -346 -390 -436 -273 -313 -351 -222 -261 -290
Capital Expenditures (CapEx)		 0.08 0.28 0.15 0.07 0.32 0.12 1.26 1.10 1.97 3.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -46 -47 -33 -31 -33 -28 -21 -16 -22 -17
Debt-free Net Working Capital (DFNWC)		 241 288 330 405 233 251 309 205 238 273
Net Working Capital (NWC)		 241 288 330 405 233 251 309 205 238 273
Net Nonoperating Expense (NNE)		 16 18 14 15 14 14 11 8.32 9.00 9.29
Net Nonoperating Obligations (NNO)		 -287 -346 -390 -436 -273 -313 -351 -222 -261 -290
Total Depreciation and Amortization (D&A)		 -1.50 -5.10 3.66 -0.33 -4.83 1.76 0.48 -0.32 -0.25 3.26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2,424.41) ($0.64) ($0.59) ($0.62) ($486.39) ($0.64) ($0.59) ($0.55) ($0.67) ($0.50)
Adjusted Weighted Average Basic Shares Outstanding		 103.94M 110.17M 99.24M 94.80M 79.74M 86.17M 74.75M 70.73M 58.83M 69.58M
Adjusted Diluted Earnings per Share		 ($2,424.41) ($0.64) ($0.59) ($0.62) ($486.39) ($0.64) ($0.59) ($0.55) ($0.67) ($0.50)
Adjusted Weighted Average Diluted Shares Outstanding		 103.94M 110.17M 99.24M 94.80M 79.74M 86.17M 74.75M 70.73M 58.83M 69.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.67) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 113.85M 110.46M 109.45M 95.61M 103.91M 86.12M 85.47M 70.95M 69.95M 69.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -53 -45 -44 -41 -42 -33 -30 -31 -26
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Cogent Biosciences' Financials

When does Cogent Biosciences's fiscal year end?

According to the most recent income statement we have on file, Cogent Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cogent Biosciences' net income changed over the last 2 years?

Cogent Biosciences' net income appears to be on an upward trend, with a most recent value of -$255.86 million in 2024, rising from -$140.24 million in 2022. The previous period was -$192.41 million in 2023. See Cogent Biosciences' forecast for analyst expectations on what’s next for the company.

What is Cogent Biosciences's operating income?
Cogent Biosciences's total operating income in 2024 was -$275.94 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $275.94 million
How has Cogent Biosciences revenue changed over the last 2 years?

Over the last 2 years, Cogent Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Cogent Biosciences have?

Cogent Biosciences' total liabilities were at $71.61 million at the end of 2024, a 28.7% increase from 2023, and a 58.9% increase since 2022.

How much cash does Cogent Biosciences have?

In the past 2 years, Cogent Biosciences' cash and equivalents has ranged from $53.23 million in 2023 to $139.89 million in 2022, and is currently $98.17 million as of their latest financial filing in 2024.

How has Cogent Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Cogent Biosciences' book value per share changed from 2.72 in 2022 to 1.32 in 2024, a change of -51.5%.


Related Companies

This page (NASDAQ:COGT) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...
GoldenCrest Metals | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
Dollar Collapse Warning: Protect Your Wealth NOW
Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...
Lear Capital | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored